微信公众号
Industrialization capability
Technical barriers
- Microstructure Design: Based on MEMS technology, smooth microstructured devices (with tip diameters less than 10 µm) are engineered to reduce the resistance to the penetration of microcrystals into the body.
- Forming process: A proprietary process and equipment enable precise fabrication of microneedle arrays at low or ambient temperatures. Combined with a specialized drying protocol, this approach effectively balances mechanical integrity and dissolution properties, overcoming key bottlenecks in mass production.
- Industrialization: A self-designed microneedle patch manufacturing system that significantly boosts production speed and output while reducing manufacturing costs.
- Core formula: Formulated with hyaluronic acid sodium of varying molecular weights and biodegradable ingredients.
Technological and Product Advantages
- The matrix is uniformly distributed, with a yield rate exceeding 98%.
- Smooth structure, with higher delivery efficiency than traditional microneedles.
- Proprietary high‑load grafting technology: breaking the limits of drug loading in microneedle physical blending.
- The transdermal delivery rate of active ingredients in medical aesthetic products exceeds 90%.
Mass-production processes and equipment with proprietary intellectual property rights
With an independently developed microneedle design and proprietary manufacturing‑process intellectual property, we ensure robust product R&D capabilities. Microneedles are fabricated and inspected using high‑resolution electron microscopy to guarantee precise formation, with rigorous quality control and optimized design to prevent voids. Our microcrystalline technology maximizes the efficacy of active ingredients while maintaining exceptional mechanical strength, enabling superior penetration into the skin.
The company’s microcrystalline technology maximizes the efficacy of its ingredients while maintaining high potency, enabling deeper penetration into the skin.
Fully automated production equipment and processes significantly reduce manufacturing costs, with a capacity of 500,000 to 1 million pairs of eye patches per month, supported by a GMP‑compliant facility rated at Class 10,000.
Novelty Pharmaceutical Co.,Ltd
Address: East Side, 4th Floor, Building 9, Nengda Biopharmaceutical Science and Technology Park, No. 9 Xindong Road, Economic and Technological Development Zone, Chongchuan District, Nantong City, Jiangsu Province
Scan it
Follow us
Visit the mobile website
Website Development:China Enterprise DynamicsNantongSEO